Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1689-1695, 2008. First published August 1, 2008; 10.1373/clinchem.2008.106328
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.106328v1
54/10/1689    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, M.-H.
Right arrow Articles by Hsu, C.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, M.-H.
Right arrow Articles by Hsu, C.-T.
(Clinical Chemistry. 2008;54:1689-1695.)
© 2008 American Association for Clinical Chemistry, Inc.

Automation and Analytical Techniques

Clinical Evaluation of Bionime Rightest GM310 Biosensors with a Simplified Electrode Fabrication for Alternative-Site Blood Glucose Tests

Ming-Hsun Wu1, Mei-Yen Fang2, Lin-Ni Jen2, Hung-Chan Hsiao2, Andreas Müller3 and Cheng-Teng Hsu2,a

1 Department of Laboratory Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan; 2 Department of Core Technical Research, Bionime Corporation, Taichung, Taiwan; 3 IMCARMED GmbH, Saalfeld, Germany.

aAddress correspondence to this author at: Department of Core Technical Research, Bionime Corporation, Taichung, Taiwan. Fax +886-4-24952568; e-mail brown.hsu{at}bionime.com.

Background: Most processes for fabricating biosensors applied to screen-printed carbon electrodes (SPCEs) are complex. This study presents a novel one-step process for manufacturing electrodes for injection-molding biosensors.

Methods: During the sensor-fabrication process, barrel-plated gold electrodes were inserted into an injection-molded base. The electrode directly touched the electrical contact of a meter. We analyzed technical measurements for this biosensor, including tests of the measurement range, within-run imprecision, and between-meter imprecision. In clinical trials, experienced technicians tested 3 alternative sites (fingertip, palm, and arm). The results were simultaneously compared with plasma values obtained with the hexokinase method on the Olympus AU640 instrument. Analytical results were evaluated according to International Standards Organization 15197 (ISO 15197:2003) criteria and by Clarke error grid analysis (EGA), and CVs were calculated to evaluate within-run imprecision.

Results: The glucose measurement range was 0.6– 33.3 mmol/L (y = 0.96x + 0.07 mmol/L; r2 = 0.9977). The CVs in the within-run imprecision test were 1.7%–3.5%, and the overall CV was 2.1%, indicating good reproducibility of results. The Student t-tests of mean values from 5 meters revealed statistically insignificant differences (P > 0.05). In clinical trials, the agreement of the Rightest GM310 meter results with those of a laboratory method complied with ISO 15197:2003 criteria. In the EGA, 100% of the values were within the acceptable zones (A + B), and the proportion of values within zone A exceeded 95%.

Conclusions: The Bionime Rightest GM310 meter applied a simplified process for biosensor fabrication and displayed acceptable performance for monitoring glucose concentrations at alternative test sites.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.